Abstract 95P
Background
The prognosis of advanced cancer including melanoma (Mel) and NSCLC has significantly improved with ICIS, leading to the emergence of new QoL issues for patients experiencing ICI-DR. The QUALICI study aimed to provide an overview of these patients’ QoL and their experiences and expectations about QoL management.
Methods
All patients with ICI-DR, defined as ICIs started for ≥2 years without subsequent treatment, were screened within 16 French sites and randomly selected to participate in this cross-sectional study. They completed questionnaires including EQ-5D-5L, Social Difficulties Inventory (SDI) and items on care and QoL management.
Results
The 234 participating patients (117 Mel; 117 NSCLC) had a mean ICI-DR of 48.8 (±14.5) months. Of them, 74.8% initiated ICI at metastatic stage and 29,5% (22.2% Mel; 36.8% NSCLC) were still treated by ICI. Most patients (NSCLC ≥62%; Mel ≥69.7%) reported no or mild issues on the 5 EQ-5D dimensions with mean Visual Analogic Scale (VAS) score of 74.8 (±19) (Mel) and 67.0 (±19.3) (NSCLC). Total SDI scores were 5.9 (±6.6) (Mel) and 10.4 (±8.5) (NSCLC) with 25% (Mel) and 50% (NSCLC) of patients presenting difficulties (score ≥10).Patients dedicated 7.7 (Mel) and 7.5 (NSCLC) hours monthly to care and assessed the burden of care at 3.1 (Mel) and 2.5 (NSCLC) on a 0-10 VAS. Two third addressed QoL issues with healthcare professionals (HP) but 21.5% could not express them as they wished. Patients prioritized closer adverse events monitoring and HP QoL training to improve QoL management (see table). Table: 95P
Patients' expectations to improve QoL management
Useful measures to improve QoL in care | NSCLC (N=117) | Melanoma (N=117) | ||
n | % | % | ||
Closer monitoring of adverse event | 65 | 58.0 | 84 | 72.4 |
QoL training for HP development | 57 | 50.9 | 61 | 55.5 |
Better coordination of the HP team | 48 | 43.6 | 55 | 50.5 |
New care method development | 47 | 42.0 | 43 | 40.6 |
Consultation dedicated to QoL | 44 | 38.9 | 47 | 41.2 |
Longer consultation | 34 | 29.8 | 44 | 38.6 |
Psychologist involvement | 33 | 29.5 | 35 | 31.0 |
Social worker support | 33 | 29.5 | 26 | 22.6 |
Tool to facilitate QoL discussions development | 30 | 27.3 | 33 | 29.7 |
Referring to discussion groups or patient associations | 29 | 25.7 | 31 | 27.0 |
Digital tool development | 22 | 19.6 | 34 | 29.6 |
Conclusions
The majority of ICI-DR patients have no or mild QoL issues, but an important proportion, especially among lung cancer patients, presents nonetheless daily life difficulties. One in five patients do not address as they wish their QoL issues with HP. Some measures prioritized by patients could improve the situation.
Legal entity responsible for the study
Bristol Myers Squibb.
Funding
Bristol Myers Squibb.
Disclosure
N. Girard: Financial Interests, Personal, Invited Speaker: AstraZeneca, BMS, MSD, Roche, Pfizer, Mirati, Amgen, Novartis, Sanofi, Gilead; Financial Interests, Personal, Advisory Board: AstraZeneca, BMS, MSD, Roche, Pfizer, Janssen, Boehringer, Novartis, Sanofi, AbbVie, Amgen, Lilly, Grunenthal, Takeda, Owkin, Leo Pharma, Daiichi Sankyo, Ipsen; Financial Interests, Institutional, Research Grant, Local: Roche, Sivan, Janssen; Financial Interests, Institutional, Funding: BMS, Leo Pharma; Financial Interests, Institutional, Research Grant: MSD; Other, Personal, Other, Family member is an employee: AstraZeneca. J. Bonastre: Financial Interests, Personal, Advisory Board, Scientific board: BMS, MSD, Janssen, Roche; Financial Interests, Institutional, Funding, Funding of the MICADO study: BMS. H. Lemasson, M. Chartier, V. Moreau-Mallet, S. Micheliza: Financial Interests, Personal, Full or part-time Employment: Bristol Myers Squibb. N. Texier, S. Hervy, M. Coin-Bavarot: Financial Interests, Personal, Full or part-time Employment, CRO in charge of the study: Kappa Santé. C. Robert: Financial Interests, Personal, Advisory Board, Consultancy fees: BMS, Roche, Pierre Fabre, Novartis, Sanofi, MSD, Pfizer, Sun Pharma, Merck, Ultimovacs, Regeneron, Egle, Philogen, Maat Pharma; Financial Interests, Personal, Other, Steering Committee: Novartis, Regeneron, Pfizer, IO Biotech; Financial Interests, Personal, Other, IDMC: Ultimovacs; Financial Interests, Personal, Invited Speaker: Pierre Fabre, Sanofi, BMS, MSD, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
88P - Utilisation of the ESMO-MCBS in prioritising immune-checkpoint inhibitors for a WHO model list of essential medicines application
Presenter: Mario Csenar
Session: Poster Display session
Resources:
Abstract
89P - Safety and efficacy of rechallenge with immune checkpoint inhibitors in advanced solid tumor: A systematic review and meta-analysis
Presenter: Huijun Xu
Session: Poster Display session
Resources:
Abstract
90P - Meta-analysis of hypophysitis incidence in melanoma patients treated with immune checkpoint inhibitors
Presenter: Vincas Urbonas
Session: Poster Display session
Resources:
Abstract
91P - Territorial disparities in the use of hospitalization at home for immune checkpoint inhibitors infusion in France between 2021 and 2022
Presenter: Anne Claire Toffart
Session: Poster Display session
Resources:
Abstract
92P - An investigation on the differences between the pre-treatment nutritional and immunological status of nasopharyngeal carcinoma patients and the healthy population
Presenter: Qiao He
Session: Poster Display session
Resources:
Abstract
93P - Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study
Presenter: Amelie Toulet
Session: Poster Display session
Resources:
Abstract
94P - Real-world characteristics, treatments and healthcare recourse utilization (HCRU) of patients (pts) with advanced/metastatic non-small cell lung cancer (mNSCLC) managed with first line (1L) immuno-oncology (IO) strategies in Greece: The IO-HORIZON study
Presenter: Dimitrios Ziogas
Session: Poster Display session
Resources:
Abstract
96P - Comparative cardiovascular risks of PD-1 vs. PD-L1 inhibitors: A meta-analysis of incidence and severity of cardiotoxicity
Presenter: Mohammedbaqer Al-Ghuraibawi
Session: Poster Display session
Resources:
Abstract
97P - Cardiac risk stratification and serial monitoring during immune checkpoint inhibitor therapy: Prospective real-world experience
Presenter: James Knott
Session: Poster Display session
Resources:
Abstract
98P - Immuno-related cardiac toxicity: a prospective study applying multiparametric cardiac MRI
Presenter: Agnese Losurdo
Session: Poster Display session
Resources:
Abstract